Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 13/20 | 0.43 |
| ▸ | PPARA | Q07869 | 10/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607000 | 0.93 | AKR1B1 (0.44) | PTGDR2PPARDPPARAPPARGAKR1B1 | |
| SCHEMBL5613620 | 0.81 | PPARD (0.45) | PTGDR2PPARDPPARAPPARGAKR1B1 | |
| SCHEMBL5613728 | 0.81 | PPARD (0.65) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL4953945 | 0.80 | PPARD (0.57) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL5613778 | 0.79 | MAOB (0.48) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL5613384 | 0.79 | PPARD (0.55) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL5606101 | 0.79 | AKR1B1 (0.49) | PTGDR2PPARDPPARAPPARGAKR1B1 | |
| SCHEMBL14215718 | 0.77 | MAPT (0.45) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL14188777 | 0.77 | PPARD (0.60) | PTGDR2PPARDPPARAPPARG | |
| SCHEMBL14188778 | 0.77 | PPARD (0.60) | PTGDR2PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014785-A1 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-01-19 | — | — | US | claimed |
| EP-1749000-A2 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060014785-A1 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2005115384-A2 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014785-A1 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | PPARG, PPARD, GPR119 | PTGDR2 959/4885PPARD 2/4885PPARA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.